medalliance | Home - MedAlliance Swiss Medical Technology

Keyword	CPC	PCC	Volume	Score	Length of keyword
medalliance	0.99	0.2	2963	33	11

Keyword	CPC	PCC	Volume	Score
medalliance	0.51	0.8	9216	67
medalliance bronx	0.06	0.3	8721	92
medalliance rennes	0.86	0.7	6507	78
medalliance albury	0.1	0.4	2643	26
medalliance cordis	1.14	0.8	1723	65
medalliance medical health services	0.67	0.3	7542	32
medalliance pharmacy	1.62	0.7	2642	20
medalliance supply	1.94	1	4212	17
medalliance selution slr	0.16	1	2853	10
medalliance bronx ny	0.85	0.4	7590	97
medalliance medical	0.82	0.5	9527	77
medalliance selution	0.95	0.6	6686	41
medalliance medical center	1.36	1	3867	97
medalliance health services	0.52	0.9	1619	77

Search Results related to medalliance on Search Engine

Home - MedAlliance Swiss Medical Technology
medalliance.com

https://medalliance.com/

WebMedAlliance is a privately-owned medical technology company. It is headquartered in Nyon, Switzerland, with offices in Germany, Singapore, UK and USA. MedAlliance has been dedicated to developing innovative drug-eluting balloons (DEBs) for patients suffering from life-threatening coronary and peripheral arterial disease.

DA: 100 PA: 22 MOZ Rank: 18 Up or Down: Up

Cordis | Cordis Announces Acquisition of MedAlliance
cordis.com

https://cordis.com/na/news/new-press-release

WebOct 17, 2022 · By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Limus Release) drug-eluting balloon. The agreement includes an initial investment of $35M and $200M payment upon closing in 2023, regulatory achievement milestones up to $125M and commercial …

DA: 99 PA: 94 MOZ Rank: 64 Up or Down: Up

MedAlliance Acquired by Cordis for up to USD 1.135 Billion
medalliance.com

https://medalliance.com/2023/10/02/medalliance-acquired-by-cordis-for-up-to-usd-1-135-billion/

Web2 October 2023 – Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of $35M and a 2023 upfront closing payment of $200M, together with regulatory achievement milestones of up to $125M and commercial milestones of up to $775M through 2029, for a total consideration of up to $1.135 Billion.

DA: 88 PA: 43 MOZ Rank: 78 Up or Down: Up

Cordis Announces the Completed Acquisition of MedAlliance
cordis.com

https://cordis.com/na/news/cordis-announces-the-completed-acquisition-of-medalliance

WebOct 2, 2023 · Miami Lakes, FL - Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced that it has completed the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology.

DA: 65 PA: 32 MOZ Rank: 30 Up or Down: Up

MedAlliance Acquired by Cordis for up to USD 1.135 Billion - PR …
prnewswire.com

https://www.prnewswire.com/news-releases/medalliance-acquired-by-cordis-for-up-to-usd-1-135-billion-301944190.html

WebGENEVA, Switzerland, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of $35M and a 2023 upfront closing payment...

DA: 10 PA: 86 MOZ Rank: 17 Up or Down: Up

Cordis Announces Acquisition of MedAlliance, Positioning Itself …
prnewswire.com

https://www.prnewswire.com/news-releases/cordis-announces-acquisition-of-medalliance-positioning-itself-for-market-leadership-in-drug-eluting-balloon-technology-301652123.html

WebOct 18, 2022 · MedAlliance is headquartered in Nyon, Switzerland. It specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products, initially...

DA: 6 PA: 9 MOZ Rank: 85 Up or Down: Up

About SELUTION SLR™ - MedAlliance Swiss Medical Technology
medalliance.com

https://medalliance.com/product/

WebMedAlliance is the first and only company able to deliver the antiproliferative drug sirolimus in a drug-eluting balloon (DEB) with a sustained release profile similar to that of a drug-eluting stent (DES). SELUTION’s technology involves the formation of spherical micro-reservoirs made from biodegradable polymer intermixed with the drug.

DA: 17 PA: 47 MOZ Rank: 70 Up or Down: Up

MedAlliance Acquired by Cordis for up to USD 1.135 Billion
yahoo.com

https://finance.yahoo.com/news/medalliance-acquired-cordis-usd-1-120000103.html

WebOct 2, 2023 · Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of $35M and a 2023 upfront closing payment of $200M, together with regulatory achievement...

DA: 5 PA: 36 MOZ Rank: 77 Up or Down: Up

Cordis Announces the Completed Acquisition of MedAlliance
prnewswire.com

https://www.prnewswire.com/news-releases/cordis-announces-the-completed-acquisition-of-medalliance-301944665.html

WebMIAMI LAKES, Fla., Oct. 2, 2023 /PRNewswire/ -- Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced that it...

DA: 19 PA: 56 MOZ Rank: 22 Up or Down: Up

Cordis to acquire MedAlliance, known for its drug-eluting …
cardiovascularbusiness.com

https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/cordis-acquire-medalliance-known-its-drug-eluting

WebMichael Walter | October 25, 2022 | Cardiovascular Business | Interventional Cardiology. Cordis has agreed to acquire MedAlliance, a Switzerland-based healthcare technology company focused on drug-eluting balloons, for an initial investment of $35 million and an upfront closing payment of $200 million.

DA: 58 PA: 42 MOZ Rank: 61 Up or Down: Down